723 related articles for article (PubMed ID: 24567435)
1. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA
J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435
[TBL] [Abstract][Full Text] [Related]
2. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
3. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
5. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
Kotsopoulos J; Gronwald J; Huzarski T; Møller P; Pal T; McCuaig JM; Singer CF; Karlan BY; Aeilts A; Eng C; Eisen A; Bordeleau L; Foulkes WD; Tung N; Couch FJ; Fruscio R; Neuhausen SL; Zakalik D; Cybulski C; Metcalfe K; Olopade OI; Sun P; Lubinski J; Narod SA;
JAMA Oncol; 2024 Apr; 10(4):484-492. PubMed ID: 38421677
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
[TBL] [Abstract][Full Text] [Related]
7. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
[TBL] [Abstract][Full Text] [Related]
8. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
[TBL] [Abstract][Full Text] [Related]
9. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
Reitsma W; de Bock GH; Oosterwijk JC; ten Hoor KA; Hollema H; Mourits MJ
Int J Gynecol Cancer; 2012 May; 22(4):579-85. PubMed ID: 22274543
[TBL] [Abstract][Full Text] [Related]
12. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
13. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
15. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract][Full Text] [Related]
16. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
18. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
[TBL] [Abstract][Full Text] [Related]
19. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
[TBL] [Abstract][Full Text] [Related]
20. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
Blok F; Roes EM; van Leenders GJ; van Beekhuizen HJ
BMC Cancer; 2016 Jan; 16():18. PubMed ID: 26768420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]